Skip to main
GOSS

GOSS Stock Forecast & Price Target

GOSS Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 29%
Hold 29%
Sell 14%
Strong Sell 0%

Bulls say

Gossamer Bio is moving towards a potential NDA submission and 3Q27 approval for its lead product seralutinib in pulmonary arterial hypertension (PAH), supported by positive data from its Phase 3 trial (PROSERA) and a successful in-person pre-NDA meeting with the FDA. The company is also addressing its balance sheet overhang through an exchange offer to reduce its outstanding convertible debt, further strengthening its financial position. While there remain risks and uncertainties, such as dilution to shareholders, the current valuation of Gossamer Bio still presents a favorable risk/reward opportunity.

Bears say

Gossamer Bio is facing risks and challenges that could impact its valuation and success in the long run. With a probability of success for their lead product at only 50% and potential dilution from a $200 million capital raise in 2027, the company's total firm value is estimated at only $1.1 billion. Additionally, there are multiple risks involved, including clinical development, commercialization, pricing, and dilution risks. A recent change in revenue and market models has also resulted in a lower price target of $1 per share and a shift to a Neutral rating from their previously held outlook of $6 per share. However, there is still potential for success if the FDA aligns with Gossamer's regulatory filing strategy and additional data shows objective improvements for PAH patients.

GOSS has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 29% recommend Buy, 29% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gossamer Bio Inc (GOSS) Forecast

Analysts have given GOSS a Buy based on their latest research and market trends.

According to 7 analysts, GOSS has a Buy consensus rating as of Jun 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gossamer Bio Inc (GOSS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.